Citrullinemia type 1 manifesting with a stroke-like episode: a case report Authors: Alaa Zayed, Hamza A Abdul-Hafez, Motea Ashhab, Imad Dweikat Published: 2026 ABSTRACT AbstractCitrullinemia type 1 (CTLN1) is a rare inherited disorder caused by mutations in the argininosuccinate synthetase 1 (ASS1) gene, disrupting the urea cycle and leading to toxic ammonia accumulation. It typically presents in newborns with lethargy, vomiting, and poor feeding. Stroke-like neurological presentations are very rare. We report a 19-month-old boy presenting with sudden right-sided weakness, lethargy, and difficulty standing. Laboratory tests revealed elevated ammonia and plasma citrulline, while brain imaging showed extensive cortical and subcortical abnormalities with cerebral edema and midline shift. Genetic testing confirmed heterozygous mutations in the ASS1 gene, diagnosing CTLN1. Prompt treatment with intravenous sodium benzoate, arginine supplementation, and dietary protein restriction led to full neurological recovery over 10 months, with resolution of motor deficits and normalization of biochemical parameters. This case highlights the importance of considering metabolic disorders in acute stroke-like presentations and the value of early biochemical and genetic diagnosis for favorable outcomes. Introduction Citrullinemia type 1 (classic citrullinemia; CTLN1) is a rare, autosomal recessive disorder characterized by a metabolic defect in the urea cycle. This defect leads to a deficiency of the cytosolic enzyme argininosuccinate synthetase 1 (ASS1), caused by mutations in the ASS1 gene [1]. The estimated incidence of this disorder is approximately 1 in 250 000 live births [1, 2]. Patients with CTLN1 typically present with hyperammonemia, leading to nausea, vomiting, seizures, and neurological symptoms like lethargy or psychiatric disturbances. However, some remain asymptomatic and are diagnosed through screening or family history. The neonatal form appears within days of birth with severe symptoms, potentially leading to coma or death if untreated. The late-onset form occurs later, often triggered by stressors like illness or high-protein intake, causing episodic hyperammonemia with behavioral and neurological changes, including altered consciousness and abnormal behavior [3, 4]. The diagnosis of CTLN1 is primarily established through plasma amino acid analysis, which shows elevated plasma levels of citrulline and glutamine, alongside reduced levels of argininosuccinic acid and arginine. Genetic testing to identify mutations in the ASS1 gene is essential for confirming the diagnosis [5]. Urea cycle disorders may exhibit characteristic findings on Magnetic Resonance Imaging (MRI), such as diffuse cortical or corpus striatum involvement on diffusion-weighted imaging (DWI), cerebral edema, cortical atrophy, delayed myelination, and insular cortex involvement [6]. To our knowledge, there have been no prior reports of stroke-like symptoms associated with CTLN1. In this case, we present a child diagnosed with CTLN1 who experienced an acute onset of right-sided weakness and decreased activity. This presentation was triggered by an upper respiratory infection and otitis media. The diagnosis was established through elevated serum ammonia levels, plasma citrulline, and glutamine observed in amino acid analysis, and was confirmed by whole-exome sequencing (WES). The patient showed significant clinical improvement after receiving treatment with sodium benzoate, arginine supplementation, and a low-protein diet. Informed consent for detailed clinical phenotyping, genetic studies, and the publication of results was obtained from the parents. Approval from the institutional review board (IRB) was granted by the Palestinian Health Research Council (PHRC/HC/518/19) in accordance with the Declaration of Helsinki and local ethical committee guidelines. This case report was submitted in accordance with the CARE criteria. Case presentation A previously healthy 19-month-old male presented with a sudden onset of right-sided weakness, hypoactivity, and an inability to bear weight for two days duration. He had an upper respiratory tract infection and otitis media before the onset of the symptoms and was treated with antibiotics. He was born to healthy first-cousin parents via an uneventful cesarean section at term following an unremarkable pregnancy and labor. The parents denied any history of trauma, fever, abnormal movement, skin rash, or previous similar symptoms. His growth and developmental milestones were normal, and his medical and vaccination history were unremarkable. A brother was diagnosed with Roifman syndrome by whole exome sequencing and died at the age of 8 months. Additionally, there was a negative family history of similar conditions. On examination, his vital signs were within normal limits. He was alert and cooperative, with spontaneous, clear speech and no evidence of aphasia or dysarthria. Cranial nerves II–XII examinations were intact. Neurological examination revealed weakness in the right upper (3/5 grade) and lower limbs (3/5 grade) with decreased deep tendon (DTR) reflexes, while normal power (5/5 grade) and DTR on the left side. In addition to unsteady gait. Glasgow Coma Scale was 15/15. Systematic examinations were unremarkable, including cardiovascular, respiratory, and gastrointestinal assessments. Initial laboratory investigations revealed an elevated serum ammonia level of 443 μmol/l and a slightly elevated lactate level of 3.4 mmol/l. Arterial blood gas analysis showed respiratory alkalosis with a pH of 7.50, PCo2 of 22.5, and HCo3 of 17.5. Plasma amino acid analysis revealed a significantly elevated plasma citrulline of 2008 μmol/l, mildly elevated plasma glutamine of 841 μmol/l, markedly elevated plasma arginine of 356.2 μmol/l and undetectable argininosuccinic acid, consistent with a diagnosis of Citrullinemia type 1. Additionally, there was an elevated liver enzyme (Table 1). Otherwise, laboratory findings were normal, including hemoglobin level, white blood cell count, serum glucose, kidney function tests, serum electrolytes, urinalysis, Cerebrospinal Fluid (CSF) analysis, and inflammatory markers. Table 1Laboratory values.ParameterValues at admissionValues at dischargeReference RangeSerum ammonia, μmol/l4437727–85 μmol/lLactate, mmol/l3.4-0.5–2.2 mmol/lSerum glucose, mg/dl88-70–110 mg/dlCRP, mg/L0.15-< 5 mg/LArterial Blood GasesArterial pH7.57.57.35–7.45Arterial pCO₂, mmHg22.53435–45 mmHgArterial HCO₃, mmol/l17.52620–24 mmol/lPlasma Amino Acid AnalysisPlasma citrulline, μmol/l2008-1–45 μmol/lPlasma glutamine, μmol/l841-254–823 μmol/lPlasma Arginine, μmol/l356.2-10–140 μmol/lArgininosuccinic acidUndetectable-1–5 μmol/lComplete Blood CountHemoglobin, g/dl11.2-9.5–15.0 g/dlWBC count, × 109/l21-6.0–19.0 × 109/lKidney function testsBUN, mg/dl9-5–18 mg/dlCreatinine, mg/dl0.3-0.2–0.7 mg/dlLiver EnzymesALT, U/l2846955–45 U/LAST, U/l3002219–80 U/LCoagulation profilePT, seconds191411–15PTT, seconds282625–40INR1.411–1.2Serum ElectrolytesSodium (Na), mmol/l138-135–145 mmol/lPotassium (K), mmol/l4.4-3.5–5.3 mmol/lCalclium (Ca), mg/dl9.5-9–11 mg/dl Laboratory values. Neuroimaging, including brain MRI, Magnetic Resonance Angiography (MRA), and Magnetic Resonance Venography (MRV), showed diffuse bilateral cortical and subcortical T2/Flair hyperintensity, predominantly in the left cerebral hemisphere, affecting the bifrontal and left parietal–temporal regions. These changes were associated with significant cortical edema, resulting in a local mass effect and midline shift to the right (Fig. 1). T2 MR images demonstrate left cortical and subcortical white matter high signal intensity, predominantly in the left temporo-occipital areas with swollen gyri. (white arrows), (A) bilateral multifocal cortical and subcortical white matter involving in the bifrontal and left temporo-occipital areas (white arrows), (B) the lesions showed increased signal on diffusion-weighted image (yellow arrows), (C) and low signal on ADC map (red arrows), (D) of the subcortical white matter related to the acute ischemic insult. WES revealed that he was double heterozygous for the two variants, p.(Gly390ARG) c.1168G > A, and p.(Pro96Thr) c.286C > A. The ASS1 gene variants c.1168G > A (p.Gly390Arg) and c.286C > A (p.Pro96Thr) are classified as missense mutations. The c.1168G > A variant causes a glycine-to-arginine substitution at position 390, and the c.286C > A variant leads to a proline-to-threonine substitution at position 96. Both variants have been associated with Citrullinemia type 1 and are classified as pathogenic or likely pathogenic based on ACMG guidelines, supported by evidence from clinical databases like HGMD and ClinVar. Family segregation analysis revealed that the mother was heterozygous for the variant p.(Gly390ARG) c.1168G < and the father and deceased brother were heterozygous for the variant p.(Pro96Thr) c.286C. The patient was diagnosed with type 1 citrullinemiawith stroke-like episode and promptly initiated on a treatment regimen that includes sodium benzoate at total dose of 250 mg/kg/day in three divided doses. Additionally, arginine supplementation was started at dose between 200 to 400 mg/kg/day divided for 3 doses, 142 mg/kg/day in our case. The patient was also placed on a low-protein diet, providing 1–1.5 g/kg/day of protein. Additionally, physiotherapy was planned for this patients as management of his weakness. On hospital day 5, the patient was in good general condition and showed marked improvement in his right-sided weakness compared to admission. Laboratory results had also improved (Table 1). Therefore, the patient was discharged on a low-protein diet, sodium benzoate (250 mg/kg/day), and arginine (180 mg/kg/day). At the 10-month follow-up, the patient was in good health, exhibiting normal cognition, behaviour, and social interaction. His neurological examination showed normal power and tone in all limbs, and he had a normal gait. Discussion Citrulline is a non-proteineous amino acid that serves as an intermediary in the arginine and urea synthesis pathways [7]. Citrullinemia is a hereditary condition in which ammonia and other toxic substances accumulate in the bloodstream [8]. It is caused by a lack of argininosuccinate synthase and mitochondrial aspartate glutamate carrier (AGC) [7]. CTLN1 includes several forms: the severe neonatal (classic) form, a milder late-onset version, cases triggered during pregnancy or postpartum, and asymptomatic forms. These variations are mainly distinguished by their clinical symptoms, although enzyme activity levels can also help predict the severity of the condition [8]. In the classic form, infants seem healthy at birth but quickly develop hyperammonemia, lethargy, poor feeding, and increased intracranial pressure, which can lead to severe neurological damage or death if untreated. Even with timely intervention and long-term management, survivors often face significant neurological challenges and potential complications like liver failure [9]. Our patient presented with a sudden onset of right-sided weakness, hypoactivity, and an inability to bear weight. Because of this unique presentation, the patient underwent additional testing for various differential diagnoses. Laboratory tests revealed elevated serum ammonia, plasma citrulline, and undetectable argininosuccinic acid. Genetic analysis revealed heterozygosity for two variants, p.(Gly390ARG) c.1168G > A and p.(Pro96Thr) c.286C > A, indicating a diagnosis of CTLN1. Atypical presentations of CTLN1 demonstrate the wide range of clinical manifestations associated with the condition. For instance, Faghfoury et al. [9] reported a case involving a 15-month-old girl who experienced encephalopathy, seizures, and fulminant liver failure. In another study, Ozturk et al. [10] associated cyanotic hypoventilation episodes with normal ammonia levels to novel mutations in the ASS1 gene. Additionally, Degirmencioglu et al. [11] described a neonate who progressed from persistent hiccups to coma, ultimately diagnosed with CTLN1 through metabolic evaluation. These cases highlight the importance of recognizing CTLN1 in diverse and atypical clinical scenarios to ensure timely diagnosis and effective treatment. Stroke-like episodes have been reported in a few cases of urea cycle disorders, including citrullinemia type I, but the underlying processes remain unclear, possibly due to neurotoxic metabolite buildup or mitochondrial malfunction [12]. Choi et al. (2006) reported a case series of two pediatric patients with citrullinemia who had MRI-confirmed ischemic lesions. Despite having appropriate therapy, both developed long-term neurological abnormalities, including microcephaly, spastic quadriparesis, and global developmental delay [13]. In contrast, our patient had clinical improvement following early intervention. In Table 2, we provided a concise differential diagnosis of acute stroke and hyperammonemia in infancy to assist clinicians in early evaluation and management (Table 2). Table 2Summarizes the differential diagnosis of acute stroke and hyperammonemia in infants.SystemDifferential DiagnosisUrgent actionsDifferential Diagnosis of Acute Stroke in InfancyVascular Causes Arterial ischemic strokeCerebral venous sinus thrombosisIntracranial hemorrhageCardioembolic stroke (congenital heart disease, endocarditis)Vascular malformations (AVM, aneurysm) ABCImmediate bedside glucose.Urgent neuroimaging: MRI brain with DWI ± MRA ± MRV if immediately available; if not, non-contrast CT (to exclude hemorrhage).Labs: CBC, electrolytes, glucose, blood gas, coagulation panel.blood cultures (if infection suspected), cardiac markers/ECG (if cardioembolic suspected).Call pediatric neurology team and pediatric neurosurgery/interventional neuroradiology. Metabolic Causes Urea cycle disorders.Organic acidemias.Mitochondrial disorders.Fatty acid oxidation defects. Infectious Causes Focal encephalitis (e.g. viral, bacterial)Acute disseminated encephalomyelitis (ADEM)Brain abscessSevere sepsis with encephalopathy/septic emboli Structural Causes Intracranial tumor/cystHydrocephalus with acute decompensation Airway/ICP management if decreased level of consciousness (head elevation, hyperosmolar therapy per ICU guidance).Urgent neuroimaging (CT if unstable; MRI if stable) to characterise lesion and hydrocephalus.Neurosurgical consult immediately. Others TraumaPost-ictal Todd’s paralysis Check for trauma/seizure historyDo bedside glucoseconsider urgent EEG if seizures or depressed consciousness (to detect non-convulsive status/help distinguish Todd’s paralysis).CT/MRI if trauma suspected.If recent seizure and focal deficit, treat ongoing seizures promptly and reassess. Differential Diagnosis of Hyperammonemia in InfantsPrimary Metabolic Disorders Urea cycle disorders.Organic acidemiasFatty acid oxidation disordersMitochondrial disorders Liver-Related Causes Acute liver failure (viral, ischemic, toxic)Chronic liver diseaseCongenital portosystemic shunt Secondary Causes SepsisSevere dehydration (usually precipitant in an underlying metabolic disorder)Medications (e.g. valproate)Total parenteral nutrition complicationsReye-like syndromes Note: In infants presenting with acute focal neurological deficits, especially when accompanied by vomiting, lethargy, respiratory alkalosis, or fluctuating consciousness, serum ammonia should be measured urgently to exclude a metabolic cause. Early recognition and prompt transfer to a tertiary metabolic center may significantly improve neurological outcomes. Summarizes the differential diagnosis of acute stroke and hyperammonemia in infants. Arterial ischemic stroke Arterial ischemic stroke Cerebral venous sinus thrombosis Cerebral venous sinus thrombosis Intracranial hemorrhage Intracranial hemorrhage Cardioembolic stroke (congenital heart disease, endocarditis) Cardioembolic stroke (congenital heart disease, endocarditis) Vascular malformations (AVM, aneurysm) Vascular malformations (AVM, aneurysm) ABC ABC Immediate bedside glucose. Immediate bedside glucose. Urgent neuroimaging: MRI brain with DWI ± MRA ± MRV if immediately available; if not, non-contrast CT (to exclude hemorrhage). Urgent neuroimaging: MRI brain with DWI ± MRA ± MRV if immediately available; if not, non-contrast CT (to exclude hemorrhage). Labs: CBC, electrolytes, glucose, blood gas, coagulation panel. Labs: CBC, electrolytes, glucose, blood gas, coagulation panel. blood cultures (if infection suspected), cardiac markers/ECG (if cardioembolic suspected). blood cultures (if infection suspected), cardiac markers/ECG (if cardioembolic suspected). Call pediatric neurology team and pediatric neurosurgery/interventional neuroradiology. Call pediatric neurology team and pediatric neurosurgery/interventional neuroradiology. Urea cycle disorders. Urea cycle disorders. Organic acidemias. Organic acidemias. Mitochondrial disorders. Mitochondrial disorders. Fatty acid oxidation defects. Fatty acid oxidation defects. Focal encephalitis (e.g. viral, bacterial) Focal encephalitis (e.g. viral, bacterial) Acute disseminated encephalomyelitis (ADEM) Acute disseminated encephalomyelitis (ADEM) Brain abscess Brain abscess Severe sepsis with encephalopathy/septic emboli Severe sepsis with encephalopathy/septic emboli Intracranial tumor/cyst Intracranial tumor/cyst Hydrocephalus with acute decompensation Hydrocephalus with acute decompensation Airway/ICP management if decreased level of consciousness (head elevation, hyperosmolar therapy per ICU guidance). Airway/ICP management if decreased level of consciousness (head elevation, hyperosmolar therapy per ICU guidance). Urgent neuroimaging (CT if unstable; MRI if stable) to characterise lesion and hydrocephalus. Urgent neuroimaging (CT if unstable; MRI if stable) to characterise lesion and hydrocephalus. Neurosurgical consult immediately. Neurosurgical consult immediately. Trauma Trauma Post-ictal Todd’s paralysis Post-ictal Todd’s paralysis Check for trauma/seizure history Check for trauma/seizure history Do bedside glucose Do bedside glucose consider urgent EEG if seizures or depressed consciousness (to detect non-convulsive status/help distinguish Todd’s paralysis). consider urgent EEG if seizures or depressed consciousness (to detect non-convulsive status/help distinguish Todd’s paralysis). CT/MRI if trauma suspected. CT/MRI if trauma suspected. If recent seizure and focal deficit, treat ongoing seizures promptly and reassess. If recent seizure and focal deficit, treat ongoing seizures promptly and reassess. Urea cycle disorders. Urea cycle disorders. Organic acidemias Organic acidemias Fatty acid oxidation disorders Fatty acid oxidation disorders Mitochondrial disorders Mitochondrial disorders Acute liver failure (viral, ischemic, toxic) Acute liver failure (viral, ischemic, toxic) Chronic liver disease Chronic liver disease Congenital portosystemic shunt Congenital portosystemic shunt Sepsis Sepsis Severe dehydration (usually precipitant in an underlying metabolic disorder) Severe dehydration (usually precipitant in an underlying metabolic disorder) Medications (e.g. valproate) Medications (e.g. valproate) Total parenteral nutrition complications Total parenteral nutrition complications Reye-like syndromes Reye-like syndromes Note: In infants presenting with acute focal neurological deficits, especially when accompanied by vomiting, lethargy, respiratory alkalosis, or fluctuating consciousness, serum ammonia should be measured urgently to exclude a metabolic cause. Early recognition and prompt transfer to a tertiary metabolic center may significantly improve neurological outcomes. Neonatal-onset hyperammonemia causes brain swelling, with MRI showing progressive abnormalities from focal to diffuse, while severe cases on CT may reveal cerebral atrophy and cortical hypoattenuation [6]. In our case, imaging showed diffuse T2/Flair hyperintensities in the left hemisphere with cortical edema causing a midline shift. The prognosis of CTLN1 depends on ammonia levels, disease form, and treatment timing. Early intervention in the neonatal form is critical to prevent severe outcomes like cognitive impairment, seizures, or death. Despite treatment, long-term complications such as neurological deficits or liver failure may occur [8]. Treatment for CTLN1 includes nitrogen scavengers like sodium benzoate and sodium phenylbutyrate, protein-restricted diets, and liver transplantation. In emergencies, hemodialysis can reduce ammonia levels [8]. Liver transplantation can improve metabolic control, quality of life, and developmental outcomes, but pre-existing neurological damage may persist [14]. The patient demonstrated significant improvement following treatment with sodium benzoate, arginine, and a low-protein diet. At the 10-month follow-up, the patient was in good health, exhibiting normal cognition, behavior, and social interactions. A neurological examination showed normal strength and muscle tone in all four limbs and a normal gait. This report describes a single patient case, which limits the ability to generalize the findings to all presentations of citrullinemia. As clinical manifestations can vary significantly among individuals, this case should be interpreted as a contribution to the broader clinical spectrum rather than a definitive representation of the disorder. Conclusion This case highlights the diagnostic challenges associated with rare presentations of CTLN1, particularly those that of stroke-like symptoms. Early recognition, supported by biochemical and genetic analyses, is essential for initiating targeted treatment.